Cargando…

Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer

BACKGROUND: Sarcopenia is commonly observed in patients with advanced‐stage epithelial ovarian cancer (EOC). However, the effect of body composition changes—during primary debulking surgery (PDS) and adjuvant platinum‐based chemotherapy—on outcomes of patients with advanced‐stage EOC is unknown. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chueh‐Yi, Yang, Yuh‐Cheng, Chen, Tze‐Chien, Chen, Jen‐Ruei, Chen, Yu‐Jen, Wu, Meng‐Hao, Jan, Ya‐Ting, Chang, Chih‐Long, Lee, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113537/ https://www.ncbi.nlm.nih.gov/pubmed/31999069 http://dx.doi.org/10.1002/jcsm.12524

Ejemplares similares

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer
por: Lee, Jie, et al.
Publicado: (2019)

Effect of Muscle Loss but Not Fat Loss during Primary Debulking Surgery and Chemotherapy on Prognosis of Patients with Ovarian Cancer
por: Nakayama, Naomi, et al.
Publicado: (2022)

Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced‐stage ovarian cancer
por: Weng, Chia‐Sui, et al.
Publicado: (2023)

Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study
por: Chang, Hao-Ting, et al.
Publicado: (2020)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

Progressive Skeletal Muscle Loss After Surgery and Adjuvant Radiotherapy Impact Survival Outcomes in Patients With Early Stage Cervical Cancer
por: Lee, Jie, et al.
Publicado: (2022)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Primary Debulking Surgery Versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals
por: Kobal, Borut, et al.
Publicado: (2018)

Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
por: Chang, Chia-Hua, et al.
Publicado: (2020)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort
por: Feng, Zheng, et al.
Publicado: (2021)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
por: Lee, Yong Jae, et al.
Publicado: (2022)

Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
por: Abbas-Aghababazadeh, Farnoosh, et al.
Publicado: (2023)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study
por: Kim, Miseon, et al.
Publicado: (2019)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
por: Menczer, Joseph, et al.
Publicado: (2011)

Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer
por: Arab, Maliheh, et al.
Publicado: (2018)

Does Endometriosis Hinder Successful Ovarian Debulking Surgery?
por: Sananpanichkul, Panya, et al.
Publicado: (2018)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
por: Lyu, Mengmeng, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery
por: Zeng, Jing, et al.
Publicado: (2017)

Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
por: Iura, Ayaka, et al.
Publicado: (2018)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer
por: Hsu, Wen‐Han, et al.
Publicado: (2023)

The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
por: Nezhat, Farr R., et al.
Publicado: (2010)

The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
por: Nakamura, Kazuto, et al.
Publicado: (2020)

Recurrent ovarian steroid cell tumor, not otherwise specified managed with debulking surgery, radiofrequency ablation, and adjuvant chemotherapy
por: Kim, Jin Suk, et al.
Publicado: (2014)

Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis
por: Lv, Xiaofeng, et al.
Publicado: (2019)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021)

Gastric Volvulus: A Delayed Surgical Complication After Debulking and Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
por: Ghattas, Souad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ttdpj74pu0boivku2kj2ujsr1p